Moderna and Merck's Personalized Cancer Vaccine Shows Promise in Late-Stage Melanoma Trial
An experimental personalized mRNA-based cancer vaccine developed by Moderna (NASDAQ: MRNA) and Merck & Co. (NYSE: MRK) has shown positive results in its first late-stage trial for melanoma patients. The combination therapy, which includes the vaccine alongside Merck's Keytruda immunotherapy, met key endpoints by significantly extending relapse-free survival compared to Keytruda alone. The phase three clinical trial involved over 1,100 high-risk or advanced melanoma patients whose cancer had been surgically removed. The treatment also reduced the risk of distant metastasis and was well tolerated with side effects similar to standard vaccines. These results build on earlier positive findings from a phase two study this year. Merck's shares rose more than 1% in premarket trading, while Moderna’s stock surged over 10%. The companies plan to present the data at an international medical conference but have not yet announced when they will seek regulatory approval. Analysts view these results as a significant milestone for both firms and potentially transformative for cancer treatment strategies.
Topics: Cancer Treatment Melanoma mRNA Vaccine Personalized Medicine